GOLDMAN SACHS GROUP INC - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 120 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$1,288,000
-15.9%
338,888
+12.7%
0.00%
Q4 2019$1,531,000
+68.6%
300,768
+67.5%
0.00%
Q3 2019$908,000
+32.2%
179,586
+61.3%
0.00%
Q2 2019$687,000
-55.9%
111,355
-66.8%
0.00%
Q1 2019$1,557,000
+25.3%
335,729
+13.5%
0.00%
Q4 2018$1,243,000
-37.6%
295,761
-6.9%
0.00%
-100.0%
Q3 2018$1,992,000
-41.8%
317,741
-25.3%
0.00%0.0%
Q2 2018$3,421,000
+104.7%
425,510
+90.0%
0.00%
Q1 2018$1,671,000
+13.2%
224,007
-9.7%
0.00%
Q4 2017$1,476,000
-7.1%
247,970
+14.9%
0.00%
Q3 2017$1,588,000
-25.3%
215,728
-31.1%
0.00%
-100.0%
Q2 2017$2,125,000
-73.0%
313,006
-62.5%
0.00%
-50.0%
Q1 2017$7,880,000
+236.2%
834,742
+207.8%
0.00%
+100.0%
Q4 2016$2,344,000
-60.6%
271,208
-71.2%
0.00%
-50.0%
Q3 2016$5,952,000
+2668.4%
940,338
+1748.0%
0.00%
Q2 2016$215,000
+138.9%
50,884
+147.2%
0.00%
Q1 2016$90,000
-89.9%
20,585
-85.8%
0.00%
Q4 2015$891,000
-14.8%
145,450
-20.5%
0.00%
Q3 2015$1,046,000
-13.7%
182,910
+12.6%
0.00%
Q2 2015$1,212,000
+140.5%
162,453
+92.9%
0.00%
Q1 2015$504,000
+13.8%
84,237
+43.7%
0.00%
Q4 2014$443,000
+74.4%
58,620
+19.8%
0.00%
Q3 2014$254,000
-0.4%
48,924
-17.4%
0.00%
Q2 2014$255,000
-7.9%
59,258
-12.4%
0.00%
Q1 2014$277,000
-54.3%
67,610
-40.5%
0.00%
Q4 2013$606,000
+40.3%
113,720
+32.1%
0.00%
Q3 2013$432,000
-75.4%
86,084
-78.1%
0.00%
-100.0%
Q2 2013$1,754,000
+59.3%
393,352
+6.5%
0.00%
Q4 2012$1,101,000
+49.8%
369,352
+44.7%
0.00%
Q3 2012$735,000
-72.2%
255,297
-5.6%
0.00%
-100.0%
Q2 2012$2,644,000
+6.5%
270,361
+7.8%
0.00%0.0%
Q1 2012$2,483,000250,7630.00%
Other shareholders

There were no reported owners of PROGENICS PHARMACEUTICALS IN in Q1 2016.

NameSharesValueWeighting ↓
View complete list of PROGENICS PHARMACEUTICALS IN shareholders